USPs that matters:

New: Rare Earth-Themefolio

Advanced IPO-Section: Equities & ETF (link)

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

IPO InfoDataHub

Short Selling Radar

Powerful & free of charge: Tools 4 WebMaster ...

Tipp: Exclusive Newswire Digest

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

KnowHow & Education
Advanced Event Calendar Feed
Mentoring & Coaches

Press

FAQ

What's New

EN
DE

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Login Register

Home
Terminal
Jaguar Health, Inc.

Jaguar Health, Inc.

WHO'M

ai

Digital Profiler. Simply click the AI button

CUSIP

47010C409

SEDOL

N/A

CIK

0001585608

jaguar.health

LEI:

New: Infographics X-Lab

FIGI: -

JAGX

Jaguar Health, Inc.

GICS: - · Sector: EQTY · Sub-Sector: -

AI

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

AI

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Jaguar Health

Click to initiate

ENTERPRISE

NAME

Jaguar Health, Inc.

ISIN

US47010C4096

TICKER

JAGX

MIC

XNAS

REUTERS

JAGX.OQ

BLOOMBERG

JAGX US

F&G: 63

6.457,71 S&P · 15,83 Vola-Index · 117.819,61 BTC · 1,16383 EURUSD

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading

Knock out & Barriers (IG)

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by ACCESS Newswire.

Thu, 14.08.2025 Jaguar Health

US47010C4096

The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 millionMytesi prescription volume increased ap...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Tue, 12.08.2025 Jaguar Health

US47010C4096

Click here to registerCompany plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Jaguar Health, I...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Thu, 10.07.2025 Jaguar Health

US47010C4096

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization for general diarrhea globallyDiarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common re...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Mon, 30.06.2025 Jaguar Health

US47010C4096

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5%The first two pati...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Thu, 26.06.2025 Jaguar Health

US47010C4096

Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurren...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Wed, 25.06.2025 Jaguar Health

US47010C4096

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogsJaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed s...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Tue, 24.06.2025 Jaguar Health

US47010C4096

Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that the maturity date has been extended fr...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Mon, 23.06.2025 Jaguar Health

US47010C4096

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25%As recently announced, initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required t...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Tue, 17.06.2025 Jaguar Health

US47010C4096

Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 18, 2025 at the Emerging Growth Conference.Participation Instructions for Jaguar's Virtual Presentation at the Emerging Gr...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

Wed, 11.06.2025 Jaguar Health

US47010C4096

Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogsJaguar in discussions with potential partners to license and fund development ...

Read More

Jaguar Health

Technical Analysis Termsheet Terminal

Permalink

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

BARRISTA SMART * AD

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ Profile QA Triggered

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 26.096 Visitors - 22.716 Registered members - 18 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Congratulation Pakistan

celebrating National Holiday

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Terms of service

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

Newsletter

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

©ayondo · THE Social Trading Pioneer · FinTech made in Germany · 2025

Consumer information

Imprint

smart.AD

Candlestick Cheatsheet
(02/2023)

Math of Gains and Losses
(02/2023)

FX-Secrets
(02/2023)

Product search
(02/2023)

Risk of Ruin
(03/2023)

Trade Calculator
(03/2023)

Suggest a Product
(03/2023)

Quality Matrix
(03/2023)

ChatGPT ayondo
(02/2023)

GPT-FAQ
(03/2023)

MQL AI
(05/2023)

MQL Library
(06/2023)

Visual Sitemap
(06/2023)

2min's FF
(07/2023)

Vola Hist
(08/2023)

DAX-Statistics
(09/2023)

Technical Analysis
(09/2023)

Technical Analysis-pro
(10/2023)

TransparentShare
(11/2023)

Dashboards^pro
(12/2023)

Most Popular
(12/2023)

Pinned⁺
(12/2023)

Bookmarks⁺
(12/2023)

NYSE A-Z
(12/2023)

PineScript AI
(Q1/2024)

SSR ^{First Timer}
(Q1/2024)

AIT-Dashboard
(Q1/2024)

Trading Simulator
(Q2/2024)

Constituents
(Q2/2024)

X-Billboard
(-)